IDL Biotech to strengthen global sales 

IDL Biotech today announced that they are strengthening their global Sales and Marketing team. Martyn Eales has been named Senior Vice President of Global Sales and Marie Torstensson has been named Marketing Manager. Together they will lead the effort to increase international sales. Read more here

 

 Patent approved in Europe

During 2015 the patent  ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034. 

IDL Biotech support CancerRehabFonden.

One  in three people in Sweden will develop cancer in their life time. Rehabilitation can help cancer patients to recover, both mentally and physically.                                CancerRehabFonden is an Swedish independent organization that provides cancer rehabilitation free of charge.

Positive results for TPS® in breast cancer study performed in Czech Republic 

Read the news here

 

 Patent approved in China

During 2015 the patent  ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. The patent has now been approved in China and is valid until 2034. Read more here

 

Positive results for UBC® Rapid

- UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours in a German multicenter study. Read more here 
- Positive results for UBC® Rapid in a Swedish multicenter study. Read more here

Claes Henning New Scientific Advisor to IDL Biotech AB

IDL Biotech continues to strengthen its scientific knowledge by appointing an additional experienced scientific advisor. Read more here.    

 

 Positive results for UBC® Rapid in an

Austrian study

Read the news  here


Oncology products

Cytokeratin Tumor markers

> TPS®

MonoTotal®

TPAcykTM

UBC®

Bacteriology products

Detection of acute typhoid fever

TUBEX® TF